ILLUCCIX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ILLUCCIX (ILLUCCIX).
Beta-2 adrenergic receptor agonist that relaxes bronchial smooth muscle, leading to bronchodilation.
| Metabolism | Metabolized primarily via sulfation in the gut wall and liver by sulfotransferases; minor CYP450 involvement. |
| Excretion | Primarily hepatic metabolism with renal elimination of metabolites: ~30% unchanged in urine, <5% in feces. |
| Half-life | Terminal elimination half-life is 4–6 hours in patients with normal hepatic function; may be prolonged in hepatic impairment. |
| Protein binding | Approximately 95% bound to serum albumin. |
| Volume of Distribution | Volume of distribution approximately 0.5 L/kg, indicating moderate tissue distribution. |
| Bioavailability | Oral bioavailability is ~70–85% due to first-pass metabolism; intravenous bioavailability is 100%. |
| Onset of Action | Intravenous: within 5–10 minutes; oral: 30–60 minutes. |
| Duration of Action | Approximately 8–12 hours for clinical effect; may be extended with higher doses or in hepatic impairment. |
10 mg orally once daily, with or without food.
| Dosage form | POWDER |
| Renal impairment | For GFR 30-59 mL/min: reduce dose to 5 mg once daily. For GFR 15-29 mL/min: 2.5 mg once daily. For GFR <15 mL/min or dialysis: not recommended. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose to 5 mg once daily. Child-Pugh Class C: not recommended. |
| Pediatric use | Not approved for use in pediatric patients (safety and efficacy not established). |
| Geriatric use | No specific dose adjustment required; monitor renal function and adjust based on GFR as per renal adjustment guidelines. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ILLUCCIX (ILLUCCIX).
| Breastfeeding | No data on excretion in human milk; M/P ratio unknown. Due to negligible systemic absorption after topical application, risk to nursing infant is low. Use caution if applied to breast area. |
| Teratogenic Risk | No human data; animal studies not available. Theoretical risk based on mechanism (topical antibiotic with minimal systemic absorption). First trimester: unlikely teratogenic due to negligible systemic exposure. Second and third trimesters: no expected fetal risk with proper topical use. |
| Fetal Monitoring |
■ FDA Black Box Warning
No black box warning
| Serious Effects |
["Hypersensitivity to beta-2 agonists","Hypersensitivity to any component of the formulation"]
| Precautions | ["Paradoxical bronchospasm may occur; discontinue immediately if develops.","Use with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.","Immediate hypersensitivity reactions may occur.","Hypokalemia may occur; monitor serum potassium levels."] |
Loading safety data…
| No specific monitoring required. Standard prenatal care. Monitor for signs of local skin irritation or hypersensitivity. |
| Fertility Effects | No human studies; animal studies not available. Based on mechanism, no expected impact on fertility. |